Bryan Giraudo Acquires 10,000 Shares of Protagonist Therapeutics Inc (PTGX) Stock

Protagonist Therapeutics Inc (NASDAQ:PTGX) Director Bryan Giraudo bought 10,000 shares of the company’s stock in a transaction on Wednesday, May 16th. The stock was bought at an average price of $6.46 per share, for a total transaction of $64,600.00. Following the completion of the purchase, the director now directly owns 10,000 shares in the company, valued at $64,600. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Shares of PTGX traded down $0.46 during mid-day trading on Thursday, hitting $5.99. The company’s stock had a trading volume of 259,926 shares, compared to its average volume of 209,881. Protagonist Therapeutics Inc has a 52-week low of $6.34 and a 52-week high of $6.50. The stock has a market capitalization of $136.76 million, a PE ratio of -2.87 and a beta of 3.54.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its quarterly earnings results on Wednesday, May 9th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.07). The firm had revenue of $10.78 million for the quarter, compared to analysts’ expectations of $10.70 million. equities analysts expect that Protagonist Therapeutics Inc will post -0.98 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently made changes to their positions in the company. Bank of Montreal Can lifted its position in shares of Protagonist Therapeutics by 1,086.0% in the 4th quarter. Bank of Montreal Can now owns 5,930 shares of the company’s stock worth $123,000 after purchasing an additional 5,430 shares during the period. Acadian Asset Management LLC purchased a new stake in shares of Protagonist Therapeutics in the 4th quarter worth approximately $197,000. Wells Fargo & Company MN lifted its position in shares of Protagonist Therapeutics by 60.8% in the 3rd quarter. Wells Fargo & Company MN now owns 9,565 shares of the company’s stock worth $169,000 after purchasing an additional 3,617 shares during the period. Cubist Systematic Strategies LLC lifted its position in shares of Protagonist Therapeutics by 255.0% in the 1st quarter. Cubist Systematic Strategies LLC now owns 11,593 shares of the company’s stock worth $100,000 after purchasing an additional 8,327 shares during the period. Finally, Prudential Financial Inc. purchased a new stake in shares of Protagonist Therapeutics in the 1st quarter worth approximately $116,000. 56.00% of the stock is owned by hedge funds and other institutional investors.

PTGX has been the topic of a number of research analyst reports. BidaskClub downgraded shares of Protagonist Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, January 19th. Stifel Nicolaus initiated coverage on shares of Protagonist Therapeutics in a research note on Monday, January 29th. They issued a “buy” rating and a $32.00 target price on the stock. BMO Capital Markets restated an “outperform” rating and issued a $42.00 target price (down from $44.00) on shares of Protagonist Therapeutics in a research note on Thursday, March 8th. Finally, Zacks Investment Research upgraded shares of Protagonist Therapeutics from a “hold” rating to a “buy” rating and set a $26.00 target price on the stock in a research note on Tuesday, March 13th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $26.75.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.

Insider Buying and Selling by Quarter for Protagonist Therapeutics (NASDAQ:PTGX)

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit